Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by gudisgoodon Jan 18, 2022 1:11pm
106 Views
Post# 34329251

RE:RE:La Presse article

RE:RE:La Presse article
MrMugsy wrote:


Good little chat - more of a review of where we've been.

Most recent numbers came from Samira - 700 employees in LATAM and 40 in Canada.
Roughtly 740 employees in early January 2022.

Let's see what happens to that number by yearend.


Thanks for the link.

Nice to see Samira interviewed even though it would have been even nicer to get a longer / more in-depth interview.

I wonder if this is translated correctly:

Q. I noticed that some company insiders, including the founder, Jonathan Goodman, and you, have made several purchases of stock lots recently. Is Knight Therapeutics' share price an issue for you?

A. Yes, absolutely, it is a significant pressure, especially for more than a year when the value of the stock has remained around $5. Three years ago, when we had only money and very little income, the stock was trading at over $10.

Why would the stock price be "an issue" and "a significant pressure" for Samira/GUD? I mean, as long as the business keeps improving...

<< Previous
Bullboard Posts
Next >>